Celsis Rapid Detection, a division of Celsis International plc has been named the Frost & Sullivan 2008 North American Growth Strategy Leadership Award recipient for Rapid Microbial Testing Methods used in the Manufacture and Release of Pharmaceuticals.
“The Celsis Rapid Detection system is a powerful and flexible technology that enables pharmaceutical companies to significantly reduce production cycle times in the manufacturing process,” said Madhu Sharma, Ph.D, industry analyst for Frost & Sullivan. “Not only does Celsis help customers get safe products to market faster, it returns bottom-line benefits like freed-up working capital while reducing inventory and safety stock requirements.”
Conventional screening for microbial contamination in raw materials, in-process work or finished goods takes an average of five days at each step. Through the use of a proprietary enzyme accelerant, the Celsis system delivers an accurate verdict in as little as 18 hours, allowing companies to run leaner and more responsive manufacturing systems.
“We are very pleased to be recognized for our leadership in rapid testing methods for pharmaceutical manufacturers,” explained Jay LeCoque, Celsis CEO. “Our customers are strong advocates of rapid methods because of the highly reliable Celsis system, our world-class service, and the simple fact that we save them significant time and money by taking days out of their manufacturing cycle times.”
Frost & Sullivan selected Celsis as a Best Practices Award recipient in the 2008 North American Growth Strategy Leadership category for the company´s focused efforts in product innovation, sales strategy, and customer support. The research and growth consulting firm also recognized Celsis´ ability to increase the market presence, regulatory acceptance, and widespread adoption of its Celsis Rapid Detection systems.
Celsis Model Identifies ROI in Advance
Frost & Sullivan cited the company´s unique financial tool, the Value Creation Model (VCM), as a key initiative driving Celsis´ growth. Designed in collaboration with consulting firm Arthur D. Little, Inc., the VCM calculates the financial return from implementing the Celsis system for rapid microbiological testing. According to Celsis customer data, adopters of the system see an average return on investment in six to nine months with a five-year net present value (NPV) of $500,000 for a single plant. These strong results, forecast by the VCM, encourage new customers to adopt the technology, and the tool has paved the way for Celsis to advance to the top of the market.
Additionally, as noted by Frost & Sullivan, the Celsis system is extremely flexible, the workflow is easy to learn, and the instruments and software are standardized, making it attractive to customers with multiple manufacturing facilities or various types of products. Also attractive is the company´s active research and development: Celsis is devising next-generation nucleic acid technologies to position itself for long-term growth.
For more information about the Celsis system, visit
www.celsis.com/rapid, where there is a link to a free whitepaper and an online “lite” version of the Value Creation Model called the Rapid Returns calculator.
